PE-PE

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Apr 5, 2023 → Oct 29, 2026

Cited window

Apr 5, 2023 → Oct 28, 2026

Retrieved

Oct 29, 2026

Title

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).

Registry

NCT05578664

Study IDs

PE-PE

Sponsor

Consorzio Oncotech

Design

Phase 2 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

85 actual

Registered

2022-10-13

Start

2023-03-14 actual

Primary completion

2028-03 estimated

Primary endpoint

Relapsed Free Survival (RFS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Not yet captured in this edition: a view on oligometastatic eligibility thresholds and relapse-free survival with pembrolizumab plus metastasis-directed treatment.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The report describes public discussion in the sources reviewed for this edition, not all HCP views or the frequency of any view. Cross-platform copies and reposts do not establish additional independent endorsements.
• –An audiovisual item's wording was available only from an initial transcript and could not be checked against a fuller transcript.
• –No full protocol document, exact-trial results publication or exact regulatory label for the pembrolizumab-plus-MDT regimen is included. The reported outcomes remain presentation-based commentary, and comments about indications do not establish regulatory status.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The endpoint terminology differs between a speaker's PFS wording and the registry's RFS wording. Another speaker's eight-cycle description also differs from the nine-cycle regimen described by the registry and another speaker; neither discrepancy is silently resolved.
• –Post dates identify when statements were shared, not when a session or readout occurred, and do not demonstrate a change in a speaker's opinion.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PE-PE" (NCT05578664), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "pe-pe-05578664". If you cannot make requests, read https://www.erudio.com/reports/pe-pe-nct05578664.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05578664", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05578664 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/pe-pe-nct05578664.json
curl https://www.erudio.com/reports/pe-pe-nct05578664.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "pe-pe-05578664" })